Acupuncture for Chemotherapy-induced Peripheral Neuropathy

Inclusion Criteria: * At least 18 years of age and have diagnosis of a lymphoma or multiple myeloma. * Patients must have chemotherapy-induced peripheral neuropathy greater or equal to 2 according to CTCAE (Common Terminology Criteria for Adverse Events) v 3.0 scale (Appendix A) in spite of previous conventional medications, e.g. Neurontin, Cymbalta and/or Lyrica. Patients receiving any of conventional medication for this symptoms must remain on the same medications throughout the study period. * Patients, or the legal guardians of patients, must have the ability to understand Korean, and be ble to provide informed consent. * ECOG (Eastern Cooperative Oncology Group) Performance Status of 0, 1, or 2. * If the patient is a woman of child-bearing potential, she must have a negative urine pregnancy test and agree to use contraception. Exclusion Criteria: * Other diseases that, in the opinion of the investigators, can cause peripheral neuropathy, such as alcoholism, diabetes mellitus, and HIV. * Current active treatment for lymphoma or multiple myeloma * Ongoing local infection at or near the acupuncture point adopted in this trial. * Severe immunocompromised patients, leukopenia ( \< 4,000/㎣) or neutropenia ( \< 1,500/㎣) * Known coagulopathy, thrombocytopenia (\< 50,000/㎣), and taking heparin (including low molecular weight heparin) or Coumadin at any dose. * Serious emotional or mental problems that precludes study entry. * Mental and physical disability that precludes accurate acupuncture. * Serious systemic diseases such as active infection, severe heart disease, uncontrolled hypertension and diabetes mellitus. * Cardiac pacemaker. * Pregnant or breastfeeding * Acupuncture therapy within the previous 30 days * Concurrent other complementary and alternative therapy such as herbal agents, high dose vitamins, and etc.